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A sustainable route to produce the scytonemin
precursor using Escherichia coli†
Sailesh Mallaa and Morten O. A. Sommer*a,b
Scytonemin is an indolic–phenolic natural product with potent pharmaceutical activities and possible
application as a sunscreen. However, the productivity of the existing synthesis systems restrains its appli-
cations in medicine and cosmetics. In this paper, we report the generation of the monomer moiety of
scytonemin from tryptophan and tyrosine in Escherichia coli. We heterologously expressed the biosyn-
thetic pathway from Nostoc punctiforme and discovered that only three enzymes from N. punctiforme
are required for the in vivo production of the monomer moiety of scytonemin in E. coli. We also found
that the constructed recombinant E. coli strains are capable of producing novel alkaloids as shunt pro-
ducts. The recombinant E. coli strain expressing the putative scytonemin biosynthetic gene cluster pro-
duced 4.2 mg L−1 (2.46 µg mg−1 dry cell weight) of the monomer moiety of scytonemin without
supplementation of extracellular substrates whereas upon supplementation with 1 mM of the substrates
to the E. coli strain harboring scyABC genes, 8.9 mg L−1 (4.56 µg mg−1 dry cell weight) of the monomer
moiety of scytonemin was produced in 5 days. Combining this cell factory with the previously described
chemical dimerization process will contribute to a sustainable production of semi-synthetic scytonemin.
Introduction
Alkaloids, a diverse group of nitrogen-containing natural pro-
ducts, are produced by a large variety of organisms including
bacteria, fungi, insects, plants and animals. Numerous alka-
loids are pharmacologically well characterized and are used as
clinical drugs, ranging from chemotherapeutics to analgesic
agents.1 Studies on plant alkaloids suggest that they are
involved in the defense mechanism against herbivores, insects
and pathogens.2 Since alkaloids are toxic, they are usually pro-
duced in small quantities by their native producer organisms.
Scytonemin is an alkaloid pigment consisting of a symmetrical
dimeric carbon skeleton composed of fused heterocyclic units
with conjugated double-bond distribution (Fig. 1) synthesized
by numerous cyanobacteria.3 Scytonemin is the first described
small molecule that inhibits human polo-like kinase 1
(PLK1).4 PLK1 has multiple functions during mitosis and plays
a significant role in maintaining the genomic stability.5
Furthermore, PLK1 is highly expressed in a broad spectrum of
cancer cells, indicating its possibility of being involved in car-
cinogenesis.6 Scytonemin (at 3–4 µM concentration) can
inhibit cell growth by cell cycle arrest in multiple myeloma
cells and renal cancer cells through specific down-regulation
of the PLK1 activity.7,8 Scytonemin is not cytotoxic (up to
10 µM) to non-proliferating cells, highlighting its possible
application in medicine.9,10 In addition to kinase inhibitory
activities, scytonemin also acts as a natural microbial sunsc-
reen by eﬀectively minimizing cellular damage caused by UV
(315–400 nm) exposure.11 Scytonemin also exhibits a radical-
scavenging activity12 and its synthesis was enhanced by oxi-
dative stress in cyanobacteria.13
The putative scytonemin biosynthetic gene cluster from
Nostoc punctiforme ATCC 29133 consists of 18 unidirectional
open reading frames (orfs) (Fig. 2). Native expression of this
gene cluster is triggered by exposure to UV light, resulting in
extracellular pigment accumulation. Once scytonemin has
reached suﬃcient quantities in the extracellular slime layer to
block the incoming UVA, the gene expression returns to back-
ground levels and halts further scytonemin synthesis.14,15 Due
to the potent UV light absorption of scytonemin, the accumu-
lated scytonemin concentration is low (∼1.3 µg mg−1 of dry
cell weight (DCW)) in currently characterized cyanobacterial
strains under laboratory culture conditions16 whereas naturally
growing colonies of a terrestrial cyanobacterium N. commune
contained only 0.4 µg mg−1 of DCW of scytonemin.17 Conse-
quently, direct extraction from natural producers is unfeasible
on a large scale. Another route to produce scytonemin is
through chemical synthesis. The total synthesis of scytonemin
has been reported from 3-indole acetic acid through a process
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comprising nine chemical steps resulting in approximately 4%
conversion to the final product.18 Accordingly, more eﬀective
approaches are desired for the continuous, rapid and cost
eﬀective production of scytonemin.
Microbial cell factories oﬀer extensive opportunities for the
industrial production of complex biomolecules for cost
eﬀective biological synthesis.19–22 Furthermore, microbial
fermentation often reduces the need for energy intensive reac-
tion conditions, toxic organic solvents, heavy metal catalysts,
and strong acids/bases, which are widely utilized in chemical
synthesis routes.23 Among the microbial cell factories
designed, the Gram-negative bacterium Escherichia coli has
become one of the most promising hosts, with a highly tract-
able genetic system and favorable fermentation conditions for
production purposes.24–26 Indeed, plant based alkaloid com-
pounds have been successfully produced from the engineered
E. coli strains. For example, 46 mg L−1 of the plant benzyliso-
quinoline alkaloid, (S)-reticuline, is produced from fermenta-
tion of metabolically engineered E. coli by utilizing simple
carbon sources such as glucose or glycerol.19 Similarly, pro-
duction of indole, a signaling molecule, from exogenous
tryptophan in E. coli has been extensively studied.27 Yields up
to 6 mM of indole have been achieved from E. coli by sup-
plementation of enough tryptophan in culture media.28 In the
present study, we described the construction of an E. coli cell
factory for bio-based production of the key pharmaceutical
intermediate, the monomer moiety of scytonemin (compound
4 in Fig. 1).
Materials and methods
Bacterial strains, plasmids, cultured conditions and chemicals
All strains, vectors and plasmids used in this study are listed
in Table 1. All DNA manipulations were carried out by follow-
ing standard protocols.29 E. coli strains were routinely cultured
in Luria–Bertani (LB) broth or on agar supplemented with the
appropriate amount of antibiotics (ampicillin 100 μg mL−1,
chloramphenicol 25 μg mL−1, streptomycin–spectinomycin
50 μg mL−1 and kanamycin 35 μg mL−1) when necessary.
M9 minimal medium was used for production of intermedi-
ates and derivatives of scytonemin. All chemicals were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). Restriction
enzymes and T4 DNA ligase were purchased from New
England Biolabs (Hertfordshire, UK) and Fermentas
(Denmark). The DNA sequence was determined on an auto-
mated DNA sequence analyzer. The authentic scytonemin stan-
dard was kindly provided by Professor Jerker Mårtensson
(Chalmer University of Technology, Sweden).
Plasmid construction
The construction of recombinant plasmids pCDF-ScyA,
pCDF-ScyAC, pCDF-ScyACD, pACYC-ScyB, pET-ScyEF,
pRSF-TyrP-DsbA, pC-ScyABC-ScyDEF, pE-GtAroB-TrpEC and
pA-TrpAB-TrpDU is described below. All PCR primers used in
this study are described in Table 2.
Based on pCDF-Duet-1, the expression recombinant
plasmid pCDF-ScyACD was constructed, which allowed the
Fig. 1 Proposed biosynthetic pathway for scytonemin and the competing shunt pathways A and B in E. coli. The shunt pathways A and B produced
new alkaloid derivatives.
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simultaneous expression of the thiamin diphosphate (ThDP)
dependent enzyme acetolactate synthase homologue, ScyA,
(NpR1276, Genbank accession no. YP_001864940), ScyC
(NpR1274, Genbank accession no. YP_001864938), and ScyD
(NpR1273, Genbank accession no. YP_001864937) from Nostoc
punctiforme ATCC 29133 in E. coli. Primer pairs ScyA_F/ScyA_R,
ScyC_F/ScyC_R and ScyD_F/ScyD_R were used for the amplifi-
cation of nucleotide sequences of scyA (1875 bp), scyC (969 bp)
and scyD (1272 bp), respectively, from the genomic DNA of
N. punctiforme. The PCR product of scyA was cloned into the
NcoI/BamHI (MCS1) sites of pCDFDuet-1 to construct the
pCDF-ScyA recombinant expression plasmid. Similarly, the PCR
product of scyC was cloned into the NdeI/BglII (MCS2) of the
pCDF-ScyA plasmid to get the pCDF-ScyAC recombinant
plasmid. The PCR product of scyD was cloned into the NdeI/
KpnI (MCS2) of pCDF-Duet-1 vector to construct the pCDF-ScyD
recombinant plasmid. Finally, using the primer pair
ScyD_F_BglII/ScyD_R and pCDF-ScyD as a template, PCR was
performed which allowed the amplification of the T7lac
sequence along with the scyD structural gene. The PCR product,
T7-rbs-ScyD, was then cloned into the BglII/KpnI sites of
pCDF-ScyAC to create the pCDF-ScyACD recombinant plasmid.
The primer pair ScyB_F/ScyB_R was used for the amplifica-
tion of the leucine dehydrogenase homologue, ScyB (NpR1275,
Genbank accession no YP_001864939), from N. punctiforme
ATCC 29133 and the PCR product was cloned into pACYC-
Duet-1 in NcoI/BamHI sites to construct the pACYC-ScyB
expression recombinant plasmid.
Similarly, the primer pairs ScyE_F/ScyE_R and ScyF_F/
ScyF_R were used to amplify scyE (NpR1272, Genbank accession
no. YP_001864936) and scyF (NpR1271, Genbank accession no.
YP_001864935) from the genomic DNA of N. punctiforme,
respectively. The PCR product of scyE was cloned into pET-Duet-
1 in NcoI/BamHI sites to construct the pET-ScyE expression
recombinant plasmid. Furthermore, the PCR product of scyF
was cloned into pRSF-ScyE excised with NdeI/BglII sites to con-
struct the pET-ScyEF expression recombinant plasmid.
Likewise, the primer pairs TyrP_F/TyrP_R and DsbA_F/
DsbA_R were used to amplify TyrP (NpR1263, Genbank acces-
sion no. YP_001864927) and DsbA (NpR1268, Genbank acces-
sion no. YP_001864932) from the genomic DNA of
N. punctiforme, respectively. The PCR products of tyrP and dsbA
were consecutively cloned into NcoI/BamHI and NdeI/BglII sites
of pRSF-Duet-1 vector to construct the pRSF-TyrP-DsbA
expression recombinant plasmid.
To express the putative scytonemin gene cluster (Fig. 2),
recombinant plasmids pC-ScyABC-ScyDEF, pE-GTAroB-TrpEC
and pA-TrpAB-TrpDU were constructed based upon
pCDF-Duet-1, pET-Duet-1 and pACYC-Duet-1 expression
vectors, respectively. The primer pairs ScyA_F/ScyC_R_BamHI,
ScyD_F/ScyF_R, GT-AroB_F/GT-AroB_R, TrpEC_F/TrpEC_R,
TrpAB_F/TrpAB_R, and TrpDU_F/TrpDU_R were used for
amplification of scyABC, scyDEF, Gt-tyrA-dsbA-aroB, trpE-trpC,
trpA-tyrP-trpB, and trpD-aroG-NpR1259 regions of the putative
scytonemin gene cluster from the genomic DNA of N. puncti-
forme, respectively. The PCR product of scyABC was cloned into
the NcoI/BamHI (MCS1) sites of pCDF-Duet-1 to construct the
pC-ScyABC recombinant expression plasmid. Further, the PCR
product of scyDEF was cloned into the NdeI/BglII (MCS2) of the
pC-ScyABC plasmid to construct pC-ScyABC-ScyDEF. Similarly,
the PCR products of Gt-tyrA-dsbA-aroB and trpE-trpC were
cloned into NcoI/BamHI (MCS1) and NdeI/BglII (MCS2) of
pET-Duet-1 vector, respectively, to construct the pE-GtAroB-Tr-
pEC recombinant plasmid. Finally, the PCR products of trpA-
tyrP-trpB and trpD-aroG-Npr1259 were cloned into NcoI/BamHI
(MCS1) and NdeI/BglII (MCS2) of the pACYC-Duet-1 vector,
respectively, to construct the pA-TrpAB-TrpDU recombinant
plasmid.
In all cases, construction of recombinant plasmids was veri-
fied by both restriction mapping and direct nucleotide sequen-
cing of respective genes in the recombinant plasmids.
Recombinant protein expression, whole-cell biotransformation,
product isolation and determination of biomass
E. coli BL21(DE3) harboring recombinant plasmids were pre-
cultured into 3 mL of LB liquid media with appropriate anti-
Fig. 2 Putative scytonemin biosynthetic gene cluster in ATCC 29133
(adapted from Soule et al., 2009). Arrows represent genes and their tran-
scriptional orientation. Blue ﬁlled arrow, regulatory gene; red ﬁlled
arrow, core structural biosynthetic gene; red open arrow, anticipated
core biosynthetic gene for ﬁnal dimerization step; green ﬁlled arrow,
glycosyltransferase; black ﬁlled arrow, aromatic amino acid biosynthetic
gene; and black open arrow, unknown function.
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biotics and incubated at 37 °C with 220 rpm overnight. The
following day 200 µL of preinoculum was transferred into
4 mL of LB liquid media (with antibiotics) and cultured at
37 °C until the optical density at 600 nm (OD600 nm) reached
approximately 0.6. Then isopropyl-β-D-thiogalactopyranoside
(IPTG) was added at a final concentration of 1 mM and the
culture was incubated at 30 °C for 20 h. The cells (∼5 × 108
cells) were harvested by centrifugation, washed with 1 mL of
phosphate buﬀer (pH 7.0) and then resuspended in 100 µL of
phosphate buﬀer. The recombinant protein was released by
following six cycles of the freeze–thaw method and checked by
SDS-PAGE (ESI Fig. S1†). For freeze–thaw cycles, the cell
Table 1 Bacterial strains and plasmids used in this study
Strains/plasmids Description Source/reference
Strains
Escherichia coli
DH5α General cloning host Invitrogen
BL21(DE3) ompT hsdT hsdS (rB
− mB
−) gal (DE3) Novagen
SM1 BL21(DE3) carrying pCDF-ScyA and pACYC-ScyB This study
SM2 BL21(DE3) carrying pCDF-ScyAC and pACYC-ScyB This study
SM3 BL21(DE3) carrying pCDF-ScyACD, pACYC-ScyB and pET-ScyEF This study
SM4 BL21(DE3) carrying pCDF-ScyACD, pACYC-ScyB, pET-ScyEF and pRSF-tyrP-dsbA This study
STN BL21(DE3) carrying pC-ScyABC-ScyDEF, pE-GtAroB-TrpEC and pA-TrpAB-TrpDU This study
Plasmids and vectors
pET-Duet-1 Double T7 promoters, ColE1 ori, Ampr Novagen
pCDF-Duet-1 Double T7 promoters, CloDF13 ori, Smr Novagen
pRSF-Duet-1 Double T7 promoters, RSF ori, Kmr Novagen
pACYC-Duet-1 Double T7 promoters, P15A ori, Cmr Novagen
pCDF-ScyA pCDF-Duet-1 carrying scyA from Nostoc punctiforme This study
pCDF-ScyAC pCDF-Duet-1 carrying scyA and scyC from N. punctiforme This study
pCDF-ScyACD pCDF-Duet-1 carrying scyA, scyC and scyD from N. punctiforme This study
pACYC-ScyB pACYC-Duet-1 carrying scyB from N. punctiforme This study
pET-ScyEF pET-Duet-1 carrying scyE and scyF from N. punctiforme This study
pRSF-TyrP-DsbA pRSF-Duet-1 carrying tyrP and dsbA from N. punctiforme This study
pC-ScyABC-ScyDEF pCDF-Duet-1 carryng scyABC and scyDEF from N. punctiforme This study
pE-GtAroB-TrpEC pET-Duet-1 carrying Gt-tyrA-dsbA-aroB and trpE-trpC from N. punctiforme This study
pA-TrpAB-TrpDU pACYC-Duet-1 carrying trpA-tyrP-trpB and trpD-aroG-Npr1259 from N. punctiforme This study
Table 2 Oligonucleotides used in this studya
Primers Oligonucleotide sequences (5′–3’) Restriction site
ScyA_F TAC̲C̲A ̲T̲G ̲G̲GCATGAGTCAAAACTATACTGGT NcoI
ScyA_R TTCG ̲G̲A ̲T̲C̲C̲TCAAACCATTGGAAATGAAAC BamHI
ScyB_F TAC̲C̲A ̲T̲G ̲G̲GCATGCTGCTATTTGAAACTGTT NcoI
ScyB_R TTCG ̲G̲A ̲T̲C̲C̲TTAAGCTGCGATCGCTTTAG BamHI
ScyC_F ATAC̲A ̲T̲A ̲T̲G ̲GAAAAAAATACTTTTGCAACA NdeI
ScyC_R TTGA ̲G̲A ̲T̲C̲T ̲TTAGTTGGGAACTAGGGATTC BglII
ScyC_R_BamHI TTGG̲G ̲A̲T ̲C̲C̲TTAGTTGGGAACTAGGGATTC BamHI
ScyD_F ATAC̲A ̲T̲A ̲T̲G ̲AAACTGAAGCCATTCACTATT NdeI
ScyD_R GAGG̲G̲T ̲A ̲C̲C̲TTAGTTGAGATTTATGGGAGGTG KpnI
ScyD_F_BglII GTA ̲G̲A̲T ̲C̲T̲ATTGTACACGGCCGCATAAT BglII
ScyE_F TAC̲C̲A ̲T̲G ̲G̲GCATGAAACTCAAATCACTTACT NcoI
ScyE_R TTCG ̲G̲A ̲T̲C̲C̲TTAGACAGTCTCTGCTTTCAC BamHI
ScyF_F ATAC̲A ̲T̲A ̲T̲G ̲GGATTAGTCAAAAATTTGTCAA NdeI
ScyF_R TTGA ̲G̲A ̲T̲C̲T ̲TCAGCATTGCTTTTGCAGTTC BglII
TyrP_F TAC̲C̲A ̲T̲G ̲G̲GCATGAAACTCCTGCTAAAATC NcoI
TyrP_R TTCG ̲G̲A ̲T̲C̲C̲TCATCTTTGCGTTTTTCTTTC BamHI
DsbA_F ATAC̲A ̲T̲A ̲T̲G ̲CTAATAGATATCTTTCATGATA NdeI
DsbA_R TTGA ̲G̲A ̲T̲C̲T ̲TCATATTTTTGCGGGTATATC BglII
GT-AroB_F TC̲C̲A ̲T ̲G̲G̲GCATGCAAATTCTGATTTATTCAT NcoI
GT-AroB_R CCTG̲G ̲A̲T ̲C̲C̲CTAAAATTCCTGCAATAGTGA BamHI
TrpEC_F TTAC̲A̲T ̲A ̲T̲G̲ATTTTTAATTCCCGTTCCTAC NdeI
TrpEC_R GTCA ̲G̲A ̲T̲C̲T ̲CTAAGAAAGCCTTAAAAGACT BglII
TrpAB_F TC̲C̲A ̲T ̲G̲G̲GCATGACCTCTATCTCCAATTCC NcoI
TrpAB_R ACAG̲G̲A ̲T̲C̲C̲TTAAGGAATCAGGACTTTGGC BamHI
TrpDU_F CTAC̲A ̲T ̲A̲T ̲G̲ATAGCTGTAACTCAAACTCCA NdeI
TrpDU_R TATA ̲G̲A ̲T̲C̲T ̲TCAAGAACGGATTAACATCGG BglII
a Restriction sites are indicated by underline and italics.
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suspension in phosphate buﬀer was frozen in a dry ice and
isopropanol bath for 5 min and thawed in a 37 °C water bath.
For whole-cell biotransformation, after IPTG induction the
culture was incubated at 30 °C for 5 h to increase biomass.
The cell pellet was collected by centrifugation and resus-
pended in M9 minimal medium (resulting in an OD600 nm of
∼1.5) with 1 mM of IPTG. The culture broth was aliquoted
(500 µL in each well) in the 96-deep-well plate (VWR,
Denmark) and supplemented with tryptophan and tyrosine
(0.5 mM or 1 mM of each). The plate was then incubated at
30 °C and 300 rpm for 5 days. The culture broth was extracted
with an equal volume of methanol for high performance
liquid chromatography (HPLC) and electrospray ionization
mass analysis.
To calculate dry cell weight (DCW) of the E. coli recombi-
nant strains, the cell pellets were collected in a pre-weighed
Eppendorf tube by centrifuging 1 ml of culture broth (combin-
ing samples from two wells) at 6000g for 10 min. Then the cell
pellets were dried at 60 °C in a vacuum oven until a constant
weight was obtained. The cell pellets were used to determine
the DCW as the biomass. Triplicate reading was carried out.
Product analysis and quantification
The bioconversion products from E. coli recombinant strains
were analyzed and quantified by HPLC (Ultimate 3000,
Thermo Scientific, USA) equipped with a Discovery® HS F5
column (4.6 × 150 mm, 5.0 µM particle size, Supelco, Sigma-
Aldrich) connected to a UV detector (260 nm, 290 nm, 360 nm
and 370 nm). A flow rate of 0.5 mL min−1 was used with a
linear gradient of 10 mM ammonium formate buﬀer (pH 3
adjusted with formic acid) (Phase A) and acetonitrile (Phase B)
by the following method: 0–3 min (25% B), 3–15 min (25–75%
B), 15–25 min (75% B), and 25–29 min (75–25% B) and
29–30 min (25% B). For quantification of metabolites, cali-
bration curves of purified compounds were drawn using 6.25,
12.5, 25, and 50 µg mL−1 concentrations. The exact mass of
the compounds were analyzed by using Oribtrap Fusion
(Thermo Scientific, USA) with a Dionex 3000 RX HPLC system
(Thermo Scientific, USA) in the positive and negative ion
modes.
Structural elucidation
The recombinant strain E. coli SM4 (E. coli BL21(DE3) harbor-
ing scyA, scyB, scyC, scyD, scyE, scyF, tyrP and dsbA) was cul-
tured in 1 L of M9 minimal media. During induction by IPTG,
500 µM of tryptophan and tyrosine were also supplemented
and after 5 days of incubation, the isolation process of the bio-
transformation product was undertaken. The culture broth
was centrifuged at 6800g for 12 min to separate supernatant
and cell pellet. Then the supernatant was extracted with an
equal volume of ethyl acetate whereas the cell pellet was
extracted with 100 mL of an ethyl acetate and acetone (3 : 1)
mixture. The organic phase was collected and concentrated to
dryness by evaporation of excess solvent. The remaining pro-
ducts were dissolved in methanol and the isolated crude
extracts from supernatant and cell pellet were combined. The
extracted crude compound was chromatographed on
PREP-HPLC (Ultimate 3000, Thermo Scientific, USA) under the
following conditions: column, Discovery® HS F5 (4.6 ×
150 mm, 5.0 µM particle size, Supelco, Sigma-Aldrich); UV
detection, 290 nm; flow rate, 1.0 mL min−1; under similar gra-
dient conditions of solvents as mentioned above. The fractions
were collected and the purified fractions were completely dried
in a SpeedVac concentrator (SAVANT SC210A, Thermo Scienti-
fic, USA). The structural elucidation of the purified com-
pounds was done by NMR analysis (1H, 13C, Correlation
Spectroscopy (COSY), Heteronuclear Single Quantum Coher-
ence (HSQC), Heteronuclear multiple-bond correlation spec-
troscopy (HMBC)) and the relative stereochemistry for
compound 4 was assigned from 1D-Nuclear Overhauser eﬀect
(NOE) experiment. The NMR analysis for structural elucidation
of compounds 5, 6, 7, 8 and 9 are described in ESI.† NMR
spectra were obtained in DMSO-d6 (Aldrich, Chicago, IL, USA)
using a Bruker Advance 600 instrument (600 MHz). For the
1H-NMR experiment, 32 transients spectra were acquired with
a spectral width of 8000 Hz. All NMR data were processed
using XWINNMR (Bruker).
Results and discussion
Heterologous expression of the putative scytonemin gene
cluster
Recent studies have shown that N. punctiforme genes have
been well expressed and functional in E. coli.30,31 Accordingly,
we chose to construct our recombinant pathway in E. coli
using the native genes of N. punctiforme. For the expression of
the putative scytonemin biosynthetic gene cluster, the recom-
binant plasmids pC-ScyABC-ScyDEF, pE-GtAroB-TrpEC and
pA-TrpAB-TrpDU were constructed, and they were transformed
into E. coli BL21 to create the strain E. coli STN. Upon IPTG
induction, the cultures of E. coli expressing the putative scyto-
nemin biosynthetic gene cluster (E. coli STN strain) in
M9 minimal media turned yellow whereas the uninduced cul-
tures did not have any color (data not shown). The metabolites
produced by E. coli STN strain were analyzed by HPLC and
mass analysis. The E. coli STN strain did not produce scytone-
min upon IPTG induction. However, the monomer of scytone-
min (compounds 4) and a new alkaloid derivative (compound
7) were produced as the dominant products from the endogen-
ous amino acids (Fig. 3).
Despite the production of compound 4, the absence of
scytonemin in the metabolites from STN was either due to the
lack of dimerization enzyme(s) in the putative scytonemin
gene cluster or inactive putative dimerization enzyme(s)
during heterologous expression in E. coli. Genome analysis
and comparison among several cyanobacterial strains for the
conserved localization in the scytonemin clusters revealed a
five-gene satellite cluster, oriented in the same transcriptional
direction in N. punctiforme.15 Of five genes in the cluster, two
genes are annotated as unknown hypothetical proteins, and
three genes are annotated as putative metal-dependent hydro-
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lase, putative prenyltransferase and putative type I phospho-
diesterase. In addition, the transcriptional studies showed that
all five genes in this cluster were upregulated under UV
irradiation.16 Hence, it was predicted that besides the putative
gene cluster shown in Fig. 2, this satellite five-gene cluster
might be involved during scytonemin biosynthesis. However,
due to unclear annotations and lack of biochemical character-
ization, the role of this satellite cluster is still ambiguous.
Expression of structural core biosynthetic genes
Comparative genomic analysis of the scytonemin gene cluster
from various cyanobacterial strains revealed that six gene pro-
ducts of ScyA-F are anticipated to produce the monomer
moiety of scytonemin, and the final reaction, i.e., dimerization
step was predicted to catalyze by tyrosinase (TyrP) and/or
oxidoreductase (DsbA) (Fig. 1).15 Accordingly, we constructed
the recombinant plasmids pACYC-ScyB, pCDF-ScyAB,
pRSF-ScyEF and pET-TyrP-DsbA and introduced them into
E. coli BL21 (DE3). The resulting strain was designated as
E. coli SM4. The in vivo isotope labeling studies in cyanobacter-
ial strains showed that both labeled tryptophan and tyrosine
were incorporated into the scytonemin structure during its bio-
synthesis.32 So, we supply tryptophan and tyrosine as precur-
sor substrates during the biotransformation of E. coli SM4.
The culture broth of E. coli SM4 strain supplemented with
these precursors turned yellow and the yellowish product was
primarily accumulated in the cell pellet (ESI Fig. S2†). HPLC
and mass analysis of the bioconversion products of SM4 strain
upon supplementation of 500 µM of tryptophan and tyrosine
accumulated compound 2 (C18H17NO3 calculated [M + H]
+:
296.12866, found: 296.12876 and calculated [M − H]−:
294.11301, found 294.11344), compound 3 (C18H15NO2 calcu-
lated [M + H]+: 278.11810, found: 278.11783), compound 4
(C18H13NO2 calculated [M + H]
+: 276.10245, found: 276.10229)
along with new alkaloid derivatives compound 5 (C26H20N2O2
calculated [M + H]+: 393.16030, found: 393.16022), compound
6 (C26H20N2O2 calculated [M + H]
+: 393.16030, found:
393.16049), compound 7 (C36H28N2O4 calculated [M + H]
+:
553.21273, found: 553.21387), compound 8 (C38H30N2O5 calcu-
lated [M + H]+: 595.22329, found: 595.22323) and compound 9
(C36H28N2O3 calculated [M + H]
+: 537.21781, found: 537.21747)
(Fig. 3A and 3B and ESI Fig. S4†). All of these five new alkaloid
derivatives have very similar UV-absorption spectra to that of
compound 3 (ESI Fig. S3†). The structure of compounds 4, 6,
7, 8 and 9 was confirmed by NMR analysis (1H, 13C, HSQC,
HMBC) (Table 3, S1–S4 and ESI Fig. S5–S10†).
The absence of scytonemin in the bioconversion products
of both SM4 and STN strains indicates that the final dimeriza-
tion step is the major bottleneck in E. coli. Structural elucida-
tion of the new alkaloid derivatives (shunt products) revealed
that all five compounds were produced from the oxidation of
intermediate compound 3, i.e., either by the formation of C–C
bond with indole or dimerization of compound 3. To gain
more information about these new derivatives such as their
synthetic origin and plausible bioactivities, we searched the lit-
erature to ascertain whether any of these compounds have
been previously reported. An anti-inflammatory drug target
IκB kinase inhibitor, PS1145, and a proteasome inhibitor,
Nostodione A, are structurally similar to the monomer moiety
Fig. 3 (A) HPLC analysis of bioconversion products from E. coli SM4
and STN strains. (i) metabolites from E. coli SM4 supplemented with
1 mM of L-tryptophan and 1 mM of L-tyrosine, (ii) metabolites from
E. coli SM4 without supplementation of substrates (control), (iii) metab-
olites from E. coli STN with IPTG induction, and (iv) metabolites from
E. coli STN without IPTG induction (control). Compounds 2, 3, 4, 5, 6, 7,
8, and 9 have a retention time of 14.2, 17.3, 18.8, 16.1, 17.8, 18.6, 20.3
and 21.1 min, respectively. (B) LC/ESI-MS analysis of metabolites from E.
coli SM4 in the positive mode: (i) exact mass of compound 3 [M + H]+
[m/z] (278.11783), (ii) exact mass of compound 4 [M + H]+ [m/z]
(276.10229), (iii) exact mass of compound 5 [M + H]+ [m/z] (393.16022),
(iv) exact mass of compound 6 [M + H]+ [m/z] (393.16049), (v) exact
mass of compound 7 [M + H]+ [m/z] (553.21387), (vi) exact mass of com-
pound 8 [M + H]+ [m/z] (595.22323), and (vii) exact mass of compound 9
[M + H]+ [m/z] (537.21747).
Paper Green Chemistry
3260 | Green Chem., 2014, 16, 3255–3265 This journal is © The Royal Society of Chemistry 2014
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
1 
A
pr
il 
20
14
. D
ow
nl
oa
de
d 
on
 2
3/
02
/2
01
5 
14
:1
0:
21
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
of scytonemin.33 Nostodione A is generated upon ozonolysis of
the reduced form of scytonemin,34 and this compound has
been isolated from N. commune35 and a fresh water cyano-
bacterium, Scytonema hofmanni.36 Similarly, the three new
scytonemin derivatives, dimethoxyscytonemin, tetramethoxy-
scytonemin and scytonin, have been identified from the
organic extracts of Scytonema sp. These compounds do not
possesses cytotoxic eﬀects even at 10 µM and also did not
inhibit the growth of Gram positive, Gram negative and fungi
at the concentration of 1 µM.37 All of these previously reported
derivatives are derived from the scytoneman skeleton of scyto-
nemin. To the best of our knowledge, all the shunt products
we found in this study have not been reported yet from any
cyanobacterial strains including N. punctiforme. So, it is
plausible that these shunt oxidation pathways are catalyzed by
E. coli endogeneous enzyme(s) consuming the accumulated
compound 3 in the cell.
Structural elucidation of compound 4
The 1H and 13C-NMR signals of compound 4 are given in
Table 3 whereas the COSY, HMBC, HSQC and NEO spectrum
are given in ESI (ESI Fig. S5†). In the 1H-NMR spectrum, the
low field singlet signals at 10.03 ppm and 10.93 ppm corre-
spond to phenyl hydroxyl and indole amide groups, respect-
ively, the signals between 7 ppm and 8 ppm correspond to
typical aromatic phenyl and indole rings and the signal at
3.51 ppm corresponds to an aliphatic signal. The COSY spec-
trum confirmed the proton observations and revealed a corre-
lation between the amide and one of the terminal protons of
the indole proton system (4 bonds apart), allowing a sequential
assignment of the proton spectrum (in fact this seems to be a
5 bond correlation from the NH to the opposite side of the
indole proton network). The HSQC correlated these proton
signals to their respective carbons, permitting the firm assign-
ment of all non-quaternary carbons. The HMBC allowed the
assignment of some quaternary signals and the observation of
a correlation between the aliphatic signal and a resonance at
204.85 ppm (only ketones resonate at this frequency). Due to
the scarcity of protons in this molecule, the fact that HMBC
signals can correlate to 2, 3 or 4 bonds apart and the cyclic
nature of the molecule, sequential assignment and structural
confirmation of the 5 membered ring becomes virtually
impossible. The presence of an indole, a phenyl and a ketone
group is indisputable, however their position could not be
ascertained so six structures as shown in Fig. 4A were possible.
At this stage a NOE spectrum was acquired. The NOE spec-
trum revealed a correlation between the amide proton and
signals of the phenyl group suggesting only possible structures
(i) and (vi) in Fig. 4A. Also, a signal was observed between the
aliphatic group and a proton on the indole ring but not with
the phenyl ring and the amide group, which strongly suggests
that the possible structure for compound 4 is structure (i) in
Fig. 4 (A) Six possible structures for compound 4 compatible with
proton, carbon, COSY, HSQC and HMBC NMR analysis. (B) Structure of
the compound 4 with atom numbering. (C) HPLC analysis of puriﬁed
compound 4 from biotransformation of E. coli SM4 at 360 nm.
Table 3 1H and 13C-NMR signals of compound 4 (600 MHz. DMSO-d6)
Position
Chemical shift (ppm)
13C 1H
1 204.85
2 36.33 3.51, s
3a 119.37
4 139.98
5 119.10 7.50, d ( J = 7.79 Hz)
6 120.01 7.07, t ( J = 7.48 Hz)
7 123.28 7.19, t ( J = 7.25 Hz)
8 112.93 7.53, d ( J = 8.20 Hz)
9 123.56
10 10.93, s
11a 139.69
12 125.54
13 124.34 6.98, s
14 125.78
15 130.64 7.63, d ( J = 8.51 Hz)
16 116.21 6.93, d ( J = 8.52 Hz)
17 158.60
18 10.03, s
a Assignments of carbon 3 and 11 may be switched.
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Fig. 4A. The confirmed structure of compound 4 along with
atom numbering is given in Fig. 4B.
Although the NMR analysis confirmed structure 4a, two iso-
meric forms i.e., keto (4a) and enol (4b) forms are feasible
structures for compound 4 as a result of keto–enol tautomeri-
zation. Owing to the lower energy, the keto form is thermo-
dynamically more stable than the enol form, so the
equilibrium heavily favors the formation of the keto form at
room temperature.38,39 In addition, the equilibrium shifts
toward the keto form in polar solvents mainly due to the invol-
vement of lone pairs (present in oxygen of the keto group) in
hydrogen bond formation with the solvent, making them less
available to form hydrogen bonds with the enol form.40,41
HPLC chromatogram of the purified compound 4 contained
two peaks: a major peak at a retention time of 18.8 min and a
minor peak at 18.5 min retention time (Fig. 4C). Regardless of
an absorbance maxima shifting (from 408 nm for major peak
to 429 nm for minor peak), both of these compounds had very
much similar UV absorbance spectra (ESI Fig. S3†). Hence,
despite the formation of both keto and enol forms of com-
pound 4, only keto form (4a) was detected in NMR analysis.
Minimal genes for the production of the scytonemin
monomer
To identify the minimal set of genes required for the pro-
duction of the monomer moiety of scytonemin, a number of
E. coli recombinant strains were constructed and their meta-
bolites were analyzed following whole-cell biotransformation
supplemented with tryptophan and tyrosine. First, the recom-
binant strain E. coli SM1 was constructed by introducing the
plasmids pACYC-ScyB and pCDF-ScyA into E. coli BL21. Upon
supplementation of tryptophan and tyrosine, this strain pre-
dominantly accumulated a decarboxylated product of inter-
mediate 1 (i.e., compounds 2a or 2b), which was detected by
HPLC at 14.2 min retention time and identified by mass analy-
sis (ESI Fig. S4†). Unlike the yellowish culture broth of SM4,
the culture broth of SM1 supplemented with tryptophan and
tyrosine was similar to the control strain (ESI Fig. S2†).
We then constructed the recombinant E. coli strains SM2
(E. coli BL21 harboring pACYC-ScyB and pCDF-ScyAC) and
SM3 (E. coli BL21 harboring pACYC-ScyB, pCDF-ScyACD and
pRSF-ScyEF). The biotransformation products of these strains
were analyzed by exogenously supplying tryptophan and tyro-
sine. The culture broth of SM2 and SM3 strains is similar to
that of the SM4, and both of these strains accumulated com-
pound 4, along with all five shunt products (compounds 5, 6,
7, 8, and 9).
The in vitro characterization of the early biosynthetic
enzymes of the scytonemin gene cluster proved that ScyB con-
verts L-tryptophan to indole-3-pyruvic acid, which is coupled
with p-hydroxyphenylpyruvic acid in the presence of ScyA to
produce a labile ß-keto acid adduct 1.42 The endogeneous
E. coli enzyme, TyrB, catalyzes deamination of tyrosine provid-
ing one of the substrates, p-hydroxyphenylpyruvic acid, for
ScyA.43 However, in the absence of ScyC, the adduct 1 under-
goes a facile, non-enzymatic decarboxylation to produce the
regioisomers 2a and 2b.44 On the other hand, in the presence
of ScyC, this non-enzymatic decarboxylation reaction is sup-
pressed in favor of an intramolecular cyclization followed by
dehydration and irreversible decarboxylation to produce com-
pound 3a.44 Although the in vitro studies on scyC only accumu-
lated 3a,44 we found that in vivo production of a monomer
moiety of scytonemin (compound 4) in E. coli can be achieved
by expression of only three genes, scyABC, from N. punctiforme.
This indicates that the endogenous enzyme(s) from the E. coli
host catalyze the oxidation reaction to convert compound 3
into compound 4. Furthermore, the dimerization reaction for
the generation of compounds 7, 8 and 9 are also likely cata-
lyzed by the E. coli endogeneous enzyme(s) instead of TyrP/
DsbA from N. punctiforme as all five shunt products were also
accumulated in the SM2 strain harboring only scyABC genes.
Comparison of compounds 4 and 7 yields
The production of the monomer moiety of scytonemin 4 and
shunt dimer compound 7 from E. coli strains SM2 and SM4
was analyzed by supplementing tryptophan and tyrosine in
M9 minimal medium at 5 days of reaction time. Utilizing
endogenous tryptophan and tyrosine, the strains can produce
compounds 4 and 7 upon IPTG induction. However, the yields
of these compounds are higher upon supplementation of
tryptophan and tyrosine. The biotransformation of strain SM2
supplemented with 500 µM of substrates produced 5.0 mg L−1
of compound 4 and 46.9 mg L−1 of compound 7 whereas at
1 mM of substrate supplementation 7.3 mg L−1 of compound
4 and 77.0 mg L−1 of compound 7 were produced. Likewise,
the strain SM4 produced 6.1 mg L−1 of compound 4 and
46.3 mg L−1 of compound 7 at 500 µM substrate supplemen-
tation whereas at 1 mM of substrate supplementation 8.9 mg
L−1 of compound 4 and 87.1 mg L−1 of compound 7 were pro-
duced (Fig. 5). On the other hand, upon IPTG induction the
strain STN produced 4.2 mg L−1 of compound 4 and 39.2 mg
L−1 of compound 7, respectively, in M9 minimal media at
5 days.
Fig. 5 Production of compounds 4 and 7 by E. coli recombinant strains
SM2 and SM4 with/without supplementation of tryptophan and tyrosine
and strain STN with/without IPTG induction.
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The biomass (DCW) of IPTG induced substrate sup-
plemented (1 mM of each) SM2 and SM4 strains were 1.84 g
L−1 and 1.94 g L−1 at 5 days whereas those of the control
strains were 1.87 g L−1 and 1.81 g L−1, respectively. Similarly,
upon IPTG induction STN strain had 1.70 g L−1 of DCW,
whereas in the absence of induction this strain had 1.86 g L−1
of DCW at 5 days. This showed the yield of 2.46 µg mg−1 DCW,
3.96 µg mg−1 DCW, and 4.56 µg mg−1 DCW of the compound
4 by STN, SM2 and SM4 strains, respectively.
Conclusions
Following our work, the final dimerization step remains a
major hurdle for the complete production of scytonemin in
E. coli. Yet commercially, many drugs such as an anticancer
drug, paclitaxel (Taxol),45 and an antimalarial drug, artemisi-
nin46 have been produced by combining the biosynthetic and
chemical synthetic approaches, highlighting the advantageous
features of the bio-chemical approach for production of
complex compounds. Our construction of a cell factory produ-
cing the monomer moiety of scytonemin could facilitate such
production when combined with the already described chemo-
synthetic dimerization step.
Upon supplementation of 1 mM of tryptophan and tyro-
sine, ca. 158 µM of compound 7 (i.e., 316 µM of the equivalent
substrate concentration), ca. 32 µM of the monomer moiety of
scytonemin, and comparable amounts of other derivatives
(compounds 2, 3, 5, 6, 8, and 9) to that of compound 4 were
produced. This indicates that nearly half of the supplemented
substrates were utilized by the heterologously expressed scyto-
nemin pathway in the constructed E. coli strain. This E. coli
cell factory has a 3.5 fold higher yield of the scytonemin
monomer moiety as compared to the scytonemin produced by
the native producer N. punctiforme. Accordingly, our work rep-
resents an important milestone towards a green scytonemin
process. However, the industrial applicability of this system
requires a maximal conversion of substrates into the targeted
product without (or low) the production of side products.
Several techniques could possibly be applied for further optim-
ization of this strain and biotransformation systems to
enhance production. For example, inactivation of the targeted
gene(s) could facilitate the production yields by preventing
metabolic flux through undesired branch pathways.47,48 Fur-
thermore, expression level optimizations of heterologous
pathway enzymes could be achieved by altering the plasmid
copy number49 and promoter strength50 and engineering the
ribosome binding sites (RBS).51 Similarly, adaptive laboratory
evolution (ALE) strategies have been broadly applied in meta-
bolic engineering of E. coli for improving fitness, yield, pro-
duction rate and cost-eﬀectiveness. The ALE techniques are
greatly eﬀective for non-native pathway optimization which
allows the selection of beneficial mutations in the production
strains in an unbiased fashion.52 Likewise, immobilization of
enzymes or whole cells has been successfully applied in
numerous scientific and industrial processes.53 Enzyme
properties such as stability, activity, specificity, selectivity, etc.
have been greatly improved by enzyme immobilization and
multi-enzyme co-localization.54,55 During biotransformation,
supplementation of high substrate concentration may have a
tendency to change the pH, osmotic pressure, etc. of culture
media (or reaction conditions), thus limiting the bioconver-
sion process. However, immobilization of the enzyme could
increase resistance to such changes and it may also increase
the enzyme concentration, which favors supplementation of
higher substrate concentrations and hence increase the
product yield. Immobilized technology has been extensively
used in bioreactors for significant improvement of the yields
in fermentation.56 In addition, systematic and careful design
in bioreactor and optimization of physical parameters such as
cultivation conditions (temperature, dissolved oxygen and
RPM), pH condition, media composition, etc. has a great
impact in the bioconversion process.57
Further in-depth studies to better understand the shunt
pathway B is essential as a majority of compound 3 was con-
sumed by this pathway. Likewise, compound 3 was also con-
sumed by forming an adduct with the indole moiety through a
shunt pathway A. Since tryptophanase is responsible for degra-
dation of L-tryptophan into indole, pyruvate and ammonia,58
the prevention of tryptophan degradation as well as the eﬀect
of shunt pathway A could be abolished by inactivation of chro-
mosomal tryptophanase (tnaA) in E. coli. These strains could
be further metabolically engineered for the overproduction of
endogenous tryptophan and the tyrosine pool.59,60 For
example, overexpression of branch pathway genes from choris-
mate to L-tyrosine and L-tryptophan can overproduce these
amino acids.61 Hence, studies on the dimerization reaction for
the complete synthesis of scytonemin in E. coli along with
pathway optimizations to improve the yield of compound 4
will be the focus of future investigations.
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